- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01416818
Treatment of Depression in Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled Study of "Xiaoyao Pill" Treatment of Depression in Patients With Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Depression as the most common non-motor comorbidity of Parkinson's disease (PD), have a negative impact on disability and quality of life.
Traditional Chinese Medicine has shown effects on several depression. It is not known if TCM also is effective for depression in PD. This study is to investigate "Xiaoyao Pill", an antidepressant in TCM, on depression in PD.
A total of 60 patients with depression in PD will be randomized to each of the three arms.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jinglin Zhang, MD, PhD.
- Phone Number: +86-10-83198677
- Email: littlenumskull@hotmail.com
Study Locations
-
-
-
Beijing, China, 100053
- Recruiting
- Xuanwu Hospital
-
Contact:
- Piu Chan, M.D., Ph.D.
- Phone Number: +86-10-83198677
- Email: pbchan@hotmail.com
-
Contact:
- Email: pbchan90@gmail.com
-
Principal Investigator:
- Piu Chan, MD,PhD.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Parkinson's disease without dementia
- Depression
- Males or females
- Willing and able to give informed consent
Exclusion Criteria:
- cognitive dysfunction
- other serious diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: group 1
|
herb extracts,were received two times a day for 12 weeks without dose changing.
|
Active Comparator: group 2
|
herb extracts, were received two times a day for 12 weeks without dose changing.
|
Placebo Comparator: group 3
|
The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Depression Scale
Time Frame: 12 weeks
|
Change of Hamilton Depression Scale score on week 12 from baseline.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the responder rate (defined as score reduction of HAMD-17>=50%)
Time Frame: 12 weeks
|
12 weeks
|
|
the Geriatric Depression Scale
Time Frame: 12 weeks
|
GDS-30
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Piu Chan, MD. PhD., Xuanwu Hospital, Beijing
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008XYRCT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression in Parkinson's Disease
-
Assiut UniversityCompletedDepression in Parkinson's DiseaseEgypt
-
ACADIA Pharmaceuticals Inc.CompletedTreatment of Depression in Adults With Parkinson's Disease (PD)United States
-
Aga Khan UniversityNot yet recruitingAnxiety Disorders | Mental Disorder in Adolescence | Depression in AdolescencePakistan
-
University of PittsburghNational Institute of Mental Health (NIMH)RecruitingDepression in Adolescence | Depression in AdultsUnited States
-
Christian BaumannCompletedAutonomic Disturbances in Parkinson's DiseaseSwitzerland
-
University Hospital, GrenobleCompletedVisual Attention in Parkinson's DiseaseFrance
-
University of CalgaryUniversity of AlbertaRecruitingDepression in AdolescenceCanada
-
Chung Shan Medical UniversityRecruitingDepression in AdolescenceTaiwan
-
Björn PhilipsLinkoeping University; Kavli TrustRecruitingDepression in AdolescenceSweden
-
Chung Shan Medical UniversityNot yet recruitingDepression in Adolescence
Clinical Trials on Xiaoyao Pill
-
University of Alabama at BirminghamCompletedObesity | Body Weight | Eating Behavior | HungerUnited States
-
Peking Union Medical College HospitalThe Second Hospital of Hebei Medical University; China-Japan Friendship Hospital and other collaboratorsUnknownAcute Ischemic StrokeChina
-
NYU Langone HealthCompleted
-
Guangzhou University of Traditional Chinese MedicineUnknownPost-stroke Patients With Motor and Sensory DysfunctionChina
-
Shanghai Jiao Tong University School of MedicineShanghai University of Traditional Chinese MedicineRecruitingPresbycusis | Age-related Hearing Loss | Hearing Disorders and DeafnessChina
-
Hvidovre University HospitalNot yet recruitingCirrhosis, Liver | Procedural Bleeding | Thrombocytopenia; Drugs
-
Andreas JosefssonGöteborg University; Umeå University; Sahlgrenska University Hospital, Sweden; Sundsvall... and other collaboratorsTerminated
-
Massachusetts General HospitalGaneden Biotech, Inc.TerminatedIrritable Bowel Syndrome | Major Depressive DisorderUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
Manan ShuklaCompletedAsthma | Chronic DiseaseUnited States